The article highlights the work of Novogenia and the career of its founder, Dr. Daniel Wallerstorfer. Driven by personal motivation – a genetically inherited kidney disease in his family – he developed a company that analyzes genetic profiles to identify individual health risks early. In addition to genetic analyses, the company offers personalized dietary supplements. The research is based on more than 23,000 genes, whose analysis provides insights into metabolism, nutrient processing, and disease risks. Through practical examples, the article demonstrates how genetic insights can help develop individualized prevention strategies.